Your Tumor's DNA might predict immunotherapy success

NCT ID NCT03578185

Recruiting now Knowledge-focused Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study looks at whether genetic markers in tumor tissue, blood, and stool can predict how well lung cancer patients respond to immunotherapy. Researchers will analyze samples from 2,000 adults with lung cancer who are receiving immune checkpoint inhibitors, searching for patterns like tumor mutation burden and immune gene signatures. The goal is to find a biomarker that could guide treatment decisions in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: immune checkpoint inhibitor (immunotherapy)
What this could lead to: If successful, this could lead to a test that helps doctors predict which lung cancer patients will benefit from immunotherapy, personalizing treatment decisions.
What could go wrong: This is an observational study, so it won't directly test a new treatment. The biomarkers identified may not prove reliable in predicting responses, and results may take time to translate into clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Asan Medical Center
NOT_YET_RECRUITING

Seoul, Songpa-gu, South Korea
Samsung Medical Center
RECRUITING

Seoul, Gangnam-gu, South Korea
Seoul National University Hospital
RECRUITING

Seoul, Joungro-gu, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.